Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Average (2016 - 2025)

Historic Equity Average for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $15.6 million.

  • Lipocine's Equity Average fell 2245.48% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 2245.48%. This contributed to the annual value of $20.7 million for FY2024, which is 2613.61% down from last year.
  • Latest data reveals that Lipocine reported Equity Average of $15.6 million as of Q3 2025, which was down 2245.48% from $18.2 million recorded in Q2 2025.
  • Lipocine's Equity Average's 5-year high stood at $44.0 million during Q1 2022, with a 5-year trough of $15.6 million in Q3 2025.
  • For the 5-year period, Lipocine's Equity Average averaged around $29.0 million, with its median value being $28.9 million (2021).
  • In the last 5 years, Lipocine's Equity Average skyrocketed by 34961.35% in 2021 and then crashed by 4152.73% in 2023.
  • Lipocine's Equity Average (Quarter) stood at $39.2 million in 2021, then fell by 6.5% to $36.6 million in 2022, then tumbled by 41.53% to $21.4 million in 2023, then decreased by 6.39% to $20.1 million in 2024, then dropped by 22.05% to $15.6 million in 2025.
  • Its Equity Average was $15.6 million in Q3 2025, compared to $18.2 million in Q2 2025 and $20.1 million in Q1 2025.